Journey Medical (DERM) Stock: Buy, Sell, or Hold?
DERM - Journey Medical Corporation Common Stock
$4.89
0.09 (1.87%)
▲
5d:
-4.59%
30d:
-24.77%
90d:
-21.0%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 11, 2026
19d
Get Alerted When DERM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DERM shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DERM shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.79
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$9.19
46.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DERM is currently trading at $4.89, which is considered oversold relative to its 30-day fair value range of $5.43 to $7.06. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.1) compared to its historical average (15.7). Remarkably, the market is currently pricing in an annual earnings decline of 23.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, DERM is showing sideways momentum. The price is currently testing key support at $4.78. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DERM scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.75 (+186.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DERM is showing sideways momentum. The price is currently testing key support at $4.78. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DERM scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.75 (+186.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.43 -
$7.06
Company Quality Score
45/100
(HOLD)
Options IV Signal
36th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
59.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 36th percentile)
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 186.5% below Wall St target ($13.75)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.43 -
$7.06
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.65
(13.2%)
Support & Resistance Levels
Support Level
$4.78
Resistance Level
$6.46
Current Trend
Sideways
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.14
Wall Street Target
$13.75
(+186.5%)
Revenue Growth (YoY)
23.3%
Profit Margin
-8.9%
Valuation Discount vs History
-23.0% cheaper
PE vs Historical
7.1 vs 15.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-23.0%
(market-implied from PE analysis)
1-Year Target
$4.32
(-10%)
2-Year Target
$3.89
(-19%)
3-Year Target
$3.50
(-27%)
3-Yr Target (if PE normalizes)
(PE: 7→16)
$7.70
(+60%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.1 to 15.7
Stabilization Target:
$10.56
(+120.0%)
PE Expansion Potential:
+120.0%
Share & Embed Analysis
Last updated: October 22, 2026 11:29 AM ET
Data refreshes hourly during market hours. Next update: 12:29 PM
Data refreshes hourly during market hours. Next update: 12:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DERM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 59 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 50 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 47 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 61 BUY |
